Objective: To evaluate the detection rate of anterior zone (AZ) prostate cancer (PCa) in patients submitted to initial and repeat transperineal prostate biopsy. Methods: From January 2013 to August 2013, 226 patients (median age 64 years) with negative digital rectal examination underwent initial (144 cases) and repeat (82 cases) transperineal prostate biopsy for PSA >10 ng/ml, PSA 4.1-10.0 or 2.6-4.0 ng/ml with free/total PSA ≤25% and ≤20%, respectively. A median of 22 versus 32 cores were performed, including 4 cores of the AZ versus 6 cores (4 anterior plus 2 cores of the transition zone, TZ) at initial versus repeat biopsy, respectively. The detection rate of PCa of the peripheral zone (PZ), AZ and TZ was prospectively evaluated. Results: The median PSA was 7.6 ng/ml; overall, a stage cT1c PCa was found in 104/226 (46%) patients, in 70 (48.6%) and 34 (41.5%) of the men who underwent initial and repeat biopsy, respectively. An AZ PCa was found in 11.5 vs. 8.8% (p = 0.32) of the patients submitted to initial versus repeat biopsy, respectively. AZ cancers demonstrated a number of positive cores (p = 0.03), greatest percentage of cancer (p = 0.001) and total percentage of cancer (p = 0.001) significantly lower in comparison with PZ PCa; moreover, 56.2 vs. 36.5% of AZ versus PZ PCa were characterized by a microfocus of cancer (p = 0.001), respectively. Conclusions: AZ biopsies increase the detection rate of PCa (about 10% of cases) at initial and repeat biopsy, allowing reduction of the biopsy false-negative rate.

Keywords:
Anterior prostate cancer, Transperineal prostate biopsy, Saturation biopsy, Anterior prostate biopsy
1.
Center MM, Jemal A, Lortet-Tieulent J, et al: International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079-1092.
2.
Schröder FH, Hugosson J, Roobol MJ, et al: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-1328.
3.
Abouassaly B, Lane BR, Jones JS: Staging saturation biopsy in patients with prostate cancer on active surveillance protocol. Urology 2008;71:573-577.
4.
Suardi N, Capitanio U, Chun FK, et al: Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features. Cancer 2008;113:2068-2072.
5.
Pepe P, Garufi A, Priolo G, et al: Prostate cancer detection at repeat biopsy: can pelvic phased-array multiparametric MRI replace saturation biopsy? Anticancer Res 2013;33:1195-1199.
6.
Pinto PA, Chung PH, Rastinehad AR, et al: Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol 2011;186:1281-1285.
7.
Hambrock T, Somford DM, Hoeks C, et al: Magnetic resonance imaging-guided prostate biopsy in men with repeat negative biopsies and increased prostate-specific antigen. J Urol 2010;185:520-527.
8.
Bott SRJ, Young MPA, Kellett MJ, et al: Anterior prostate cancer: is it more difficult to diagnose? BJU Int 2002;89:886-889.
9.
Pepe P, Aragona F: Incidence of insignificant prostate cancer using free/total PSA: results of a case-finding protocol on 14,453 patients. Prostate Cancer Prostatic Dis 2010;13:316-319.
10.
Pepe P, Aragona F: Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation. Urology 2007;70:1131-1135.
11.
Pepe P, Fraggetta F, Galia A, et al: Is quantitative histologic examination useful to predict nonorgan-confined prostate cancer when saturation biopsy is performed? Urology 2008;72:1198-1202.
12.
Lee AK, Doytchinova T, Chen M, et al: Can the core length involved with prostate cancer identify clinically insignificant disease in low risk patients diagnosed on the basis of a single positive core? Urol Oncol 2003;21:123-127.
13.
Dindo D, Demartines N, Clavien PA: Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205-213.
14.
Al-Ahmadie HA, Tickoo SK, Olgac S, et al: Anterior-predominant prostatic tumors: zone of origin and pathologic outcomes at radical prostatectomy. Am J Surg Pathol 2008;32:229-235.
15.
McNeal JE: The prostate and prostatic urethra: a morphologic synthesis. J Urol 1972;107:1008-1016.
16.
Tiguert R, Kabbani W, Sakr W, et al: Origin and racial distribution of glandular tissue in the anterior compartment of the prostate: an autopsy study. Prostate 1999;39:310-315.
17.
Fine SW, Reuter VE: Anatomy of the prostate revisited: implications for prostate biopsy and zonal origins of prostate cancers. Histopathology 2012;60:142-152.
18.
Bouyé S, Potiron E, Puech P, et al: Transition zone and anterior stromal prostate cancers: zone of origin and intraprostatic patterns of spread at histopathology. Prostate 2009;69:105-113.
19.
Mai KT, Moazin M, Morash C, et al: Transitional zone and anterior peripheral zone of the prostate. A correlation of small-volume cancer in the biopsy cores and high PSA with positive anterior margins in radical prostatectomy specimens. Urol Int 2001;66:191-196.
20.
Koppie TM, Bianco FJ Jr, Kuroiwa K, et al: The clinical features of anterior prostate cancers. BJU Int 2006;98:1167-1171.
21.
Sundi D, Ross AE, Humphreys EB, et al: African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol 2013;31:2991-2997.
22.
Iremashvili V, Pelaez L, Jordá M, et al: Prostate cancers of different zonal origin: clinicopathological characteristics and biochemical outcome after radical prostatectomy. Urology 2012;80:1063-1069.
23.
Komai Y, Numao N, Yoshida S, et al: High diagnostic ability of multiparametric magnetic resonance imaging to detect anterior prostate cancer missed by transrectal 12-core biopsy. J Urol 2013;190:867-873.
24.
Pepe P, Aragona F: Morbidity after transperineal prostate biopsy in 3000 patients undergoing 12 vs 18 vs more than 24 needle cores. Urology 2013;81:1142-1146.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.